Breaking News

Orexo, AZ in Respiratory Research Pact

January 25, 2013

AZ takes on preclinical development of OX-CLI program

Orexo AB has entered into an agreement with AstraZeneca for its OX-CLI preclinical program for the potential treatment of respiratory diseases. AZ has been granted rights to conduct further preclinical research and evaluation of compounds in Orexo’s OX-CLI program. AZ also has an option to acquire the compounds, subject to a full asset transfer agreement, under which Orexo will receive development milestones and royalties on future revenues. Financial terms were not disclosed.
 
“Our OX-CLI program is a promising R&D project, which has potential to improve the treatment of respiratory diseases for millions of patients. AstraZeneca, a leading global company within the inflammatory and respiratory area, is the optimal partner for OX-CLI and we look forward to see the project advancing,” said chief executive officer Anders Lundström.

Related Contract Manufacturing:

  • CROs and Today’s  R&D Landscape

    CROs and Today’s R&D Landscape

    Kristin Brooks, Associate Editor, Contract Pharma||November 9, 2016
    John Lewis of ACRO discusses opportunities, challenges, and the future CRO

  • The Human Parts of Mouse Models

    The Human Parts of Mouse Models

    Julia Schueler, Head of in vivo Operations, Oncotest, a Charles River company ||October 11, 2016
    The PDX model system has come back into focus

  • Choosing Oral Formulations for First-in-man Clinical Trials

    Choosing Oral Formulations for First-in-man Clinical Trials

    Jon Sutch, Senior Manager of Formulation Development, Patheon||October 11, 2016
    Early formulations should be simple, but selecting a simple formulation isn’t as easy as it seems